Ikarian Capital, LLC Intercept Pharmaceuticals, Inc. Transaction History

Ikarian Capital, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$9.17 - $19.29 $687,750 - $1.45 Million	75,000 Added 88.03%	160,200 $1.77 Million
Q3 2022 Nov 14, 2022	SELL	$12.21 - $19.7 $241,758 - $390,060	-19,800 Reduced 18.86%	85,200 $1.19 Million
Q2 2022 Aug 12, 2022	BUY	$11.23 - $19.59 $784,426 - $1.37 Million	69,851 Added 198.73%	105,000 $1.45 Million
Q1 2022 May 13, 2022	BUY	$13.37 - $17.79 $7,808 - $10,389	584 Added 1.69%	35,149 $572,000
Q3 2021 Nov 15, 2021	SELL	$12.99 - $20.47 $5,650 - $8,904	-435 Reduced 1.24%	34,565 $513,000
Q1 2021 May 17, 2021	BUY	$19.33 - $37.75 $676,549 - $1.32 Million	35,000 New	35,000 $808,000

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.